ES2375627T3 - Anticuerpos anti-abeta. - Google Patents

Anticuerpos anti-abeta. Download PDF

Info

Publication number
ES2375627T3
ES2375627T3 ES05723280T ES05723280T ES2375627T3 ES 2375627 T3 ES2375627 T3 ES 2375627T3 ES 05723280 T ES05723280 T ES 05723280T ES 05723280 T ES05723280 T ES 05723280T ES 2375627 T3 ES2375627 T3 ES 2375627T3
Authority
ES
Spain
Prior art keywords
antibody
peptide
cells
gel
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05723280T
Other languages
English (en)
Spanish (es)
Inventor
Ronald Bradley Demattos
Uma Kuchibhotla
Hsiu-Chiung Yang
Don B. Mcclure
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2375627T3 publication Critical patent/ES2375627T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
ES05723280T 2004-02-23 2005-02-17 Anticuerpos anti-abeta. Expired - Lifetime ES2375627T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23
US546764P 2004-02-23
PCT/US2005/005198 WO2005082939A2 (en) 2004-02-23 2005-02-17 Anti-abeta antibody

Publications (1)

Publication Number Publication Date
ES2375627T3 true ES2375627T3 (es) 2012-03-02

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05723280T Expired - Lifetime ES2375627T3 (es) 2004-02-23 2005-02-17 Anticuerpos anti-abeta.

Country Status (20)

Country Link
US (1) US20070190046A1 (https=)
EP (1) EP1720909B1 (https=)
JP (1) JP4851348B2 (https=)
KR (2) KR20090005410A (https=)
CN (1) CN1922209B (https=)
AT (1) ATE534667T1 (https=)
AU (1) AU2005217596B2 (https=)
BR (1) BRPI0507856A (https=)
CA (1) CA2556436C (https=)
CY (1) CY1112162T1 (https=)
DK (1) DK1720909T3 (https=)
EA (1) EA009872B1 (https=)
ES (1) ES2375627T3 (https=)
IL (1) IL177611A (https=)
NO (1) NO20064239L (https=)
PL (1) PL1720909T3 (https=)
PT (1) PT1720909E (https=)
SI (1) SI1720909T1 (https=)
UA (1) UA93181C2 (https=)
WO (1) WO2005082939A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
KR20120017469A (ko) 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
JP2010515717A (ja) 2007-01-11 2010-05-13 フィリップス−ウニベルジテート・マールブルク アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
RS53174B (sr) 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
JP5773879B2 (ja) 2008-11-25 2015-09-02 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 神経系の細胞の生存を促進するためのＤＲ６およびｐ７５のアンタゴニストの使用
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
KR20120103587A (ko) 2009-11-12 2012-09-19 제넨테크, 인크. 수상돌기 소극 밀도를 증진시키는 방법
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
PT3042917T (pt) * 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
HUE041391T2 (hu) 2011-06-23 2019-05-28 Biogen Int Neuroscience Gmbh Anti-alfa-szinukleinkötõ molekulák
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
CA2883896C (en) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
EP4331605A3 (en) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
JP2019524788A (ja) * 2016-08-11 2019-09-05 イーライ リリー アンド カンパニー アミノチアジンおよびｂａｃｅ１阻害剤としてのそれらの使用
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002100B1 (ru) 1996-12-23 2001-12-24 Элан Фармасьютикалз, Инк. ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
BRPI0108676B8 (pt) * 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide

Also Published As

Publication number Publication date
CN1922209B (zh) 2012-09-05
DK1720909T3 (da) 2012-01-30
PL1720909T3 (pl) 2012-04-30
WO2005082939A2 (en) 2005-09-09
IL177611A (en) 2013-05-30
AU2005217596A1 (en) 2005-09-09
AU2005217596B2 (en) 2012-01-19
KR100889430B1 (ko) 2009-03-23
SI1720909T1 (sl) 2012-01-31
CY1112162T1 (el) 2015-12-09
CN1922209A (zh) 2007-02-28
KR20060126785A (ko) 2006-12-08
BRPI0507856A (pt) 2007-07-10
CA2556436C (en) 2014-04-01
KR20090005410A (ko) 2009-01-13
EP1720909A2 (en) 2006-11-15
EA009872B1 (ru) 2008-04-28
PT1720909E (pt) 2011-12-23
EA200601545A1 (ru) 2007-02-27
CA2556436A1 (en) 2005-09-09
JP2008500279A (ja) 2008-01-10
WO2005082939A3 (en) 2005-10-27
NO20064239L (no) 2006-11-20
UA93181C2 (ru) 2011-01-25
EP1720909B1 (en) 2011-11-23
US20070190046A1 (en) 2007-08-16
IL177611A0 (en) 2006-12-10
JP4851348B2 (ja) 2012-01-11
ATE534667T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
ES2375627T3 (es) Anticuerpos anti-abeta.
ES2567437T3 (es) Oligómeros beta-(1,42) amiloides, derivados de los mismos y anticuerpos para estos, métodos para la preparación de los mismos y uso de los mismos
JP5475994B2 (ja) 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
ES2632625T3 (es) Composición para su uso en el tratamiento de una enfermedad
KR101370253B1 (ko) 재조합 항체의 재접힘 방법
ES2899227T3 (es) Anticuerpos anti sortilina y métodos de uso de los mismos
UA124616C2 (uk) Зв&#39;язуюче тау-білок антитіло
JP2010511386A (ja) 新規Ａβ配座異性体選択的抗Ａβグロブロマーモノクローナル抗体
JP2019507107A (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体及びその使用
JP2017509594A (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
EA032054B1 (ru) Моноклональное антитело или его антигенсвязывающий фрагмент, его применения, клеточная линия гибридомы для его получения, фармацевтическая композиция, содержащая моноклональное антитело или его антигенсвязывающий фрагмент, способ диагностики in vitro амилоид-ассоциированного заболевания и набор для его осуществления
WO2021012082A1 (zh) β—淀粉样蛋白环状核糖核酸、多肽及其应用
CN115803347A (zh) 抗klk2抗体的抗独特型抗体
MXPA06009560A (en) Anti-abeta antibody
WO2010038831A1 (ja) 細胞増殖を伴う糖尿病合併症の検査のための方法、組成物およびキット
EP4537842A1 (en) Preventative agent or therapeutic agent for amyotrophic lateral sclerosis, parkinson&#39;s disease, huntington&#39;s disease, spinocerebellar ataxia, aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging
US20240025985A1 (en) Agent for Preventing or Treating Frontotemporal Lobar Degeneration
ES2530141B1 (es) Péptido útil como diana farmacológica para el cribado de moléculas para el tratamiento y/o prevención de la enfermedad de Alzheimer, anticuerpo frente al mismo y uso del anticuerpo para el tratamiento y/o prevención de dicha enfermedad.
HK40125870A (zh) 肌萎缩侧索硬化症、帕金森病、亨廷顿病、脊髓小脑性共济失调、与老化有关的变性疾病或神经疾病、脑老化、或者伴有脑老化的疾病的预防剂或治疗剂
AU2012201856A1 (en) Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies